Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease.

IF 3.2 3区医学 Q2 GASTROENTEROLOGY & HEPATOLOGY

Gut and Liver Pub Date : 2025-09-17 DOI:10.5009/gnl250188

Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon

{"title":"Real-World Experience of Switching from Intravenous to Subcutaneous Vedolizumab in Korean Patients with Inflammatory Bowel Disease.","authors":"Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Sung Wook Hwang, Hyuk Yoon","doi":"10.5009/gnl250188","DOIUrl":null,"url":null,"abstract":"Background/aims: Subcutaneous (SC) vedolizumab (VDZ) has recently become available for patients with inflammatory bowel disease (IBD) in Korea. This retrospective observational study aimed to evaluate the clinical outcomes and safety of switching from intravenous (IV) to SC VDZ.Methods: Patients with IBD who switched from IV to SC VDZ between 2023 and 2024 were included. The primary outcome was the 24-week persistence rate of SC VDZ. Secondary outcomes included clinical factors associated with SC VDZ persistence, safety profiles, subsequent treatment courses after discontinuation of SC VDZ, and recapture success rate after reverting to IV VDZ.Results: A total of 101 patients with IBD (72 with ulcerative colitis [UC] and 29 with Crohn's disease) were included. After 24 weeks, 72 patients (71.3%) maintained SC VDZ. Corticosteroid use at switching was the strongest predictor of 24-week SC VDZ failure in both the overall IBD cohort (p=0.018) and in patients with UC (p=0.027) in multivariable analyses. Kaplan-Meier analysis showed that patients with UC with intensified IV dosing intervals (p=0.021), failure to clinical remission (p=0.038), or concomitant corticosteroid use at switching (p<0.001) were more likely to discontinue SC VDZ. Injection-site reactions occurred in 24 patients (23.8%). A total of 34 patients (33.7%) discontinued SC VDZ; 19 resumed IV VDZ; and 13 initiated another advanced therapy. The recapture success rate after reverting to IV VDZ was 73.7%, with higher success in those who discontinued because of injection-site reactions or poor adherence.Conclusions: SC VDZ persistence is significantly influenced by disease activity at the time of switching.","PeriodicalId":12885,"journal":{"name":"Gut and Liver","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gut and Liver","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5009/gnl250188","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: Subcutaneous (SC) vedolizumab (VDZ) has recently become available for patients with inflammatory bowel disease (IBD) in Korea. This retrospective observational study aimed to evaluate the clinical outcomes and safety of switching from intravenous (IV) to SC VDZ.

Methods: Patients with IBD who switched from IV to SC VDZ between 2023 and 2024 were included. The primary outcome was the 24-week persistence rate of SC VDZ. Secondary outcomes included clinical factors associated with SC VDZ persistence, safety profiles, subsequent treatment courses after discontinuation of SC VDZ, and recapture success rate after reverting to IV VDZ.

Results: A total of 101 patients with IBD (72 with ulcerative colitis [UC] and 29 with Crohn's disease) were included. After 24 weeks, 72 patients (71.3%) maintained SC VDZ. Corticosteroid use at switching was the strongest predictor of 24-week SC VDZ failure in both the overall IBD cohort (p=0.018) and in patients with UC (p=0.027) in multivariable analyses. Kaplan-Meier analysis showed that patients with UC with intensified IV dosing intervals (p=0.021), failure to clinical remission (p=0.038), or concomitant corticosteroid use at switching (p<0.001) were more likely to discontinue SC VDZ. Injection-site reactions occurred in 24 patients (23.8%). A total of 34 patients (33.7%) discontinued SC VDZ; 19 resumed IV VDZ; and 13 initiated another advanced therapy. The recapture success rate after reverting to IV VDZ was 73.7%, with higher success in those who discontinued because of injection-site reactions or poor adherence.

Conclusions: SC VDZ persistence is significantly influenced by disease activity at the time of switching.

查看原文本刊更多论文

韩国炎症性肠病患者从静脉注射转为皮下注射Vedolizumab的实际经验

背景/目的：在韩国，皮下（SC） vedolizumab （VDZ）最近可用于炎症性肠病（IBD）患者。这项回顾性观察性研究旨在评估从静脉注射（IV）切换到SC VDZ的临床结果和安全性。方法：纳入了2023年至2024年间从IV切换到SC VDZ的IBD患者。主要终点是SC VDZ的24周持续率。次要结局包括与SC VDZ持续性相关的临床因素、安全性、SC VDZ停药后的后续疗程以及恢复静脉VDZ后的再服药成功率。结果：共纳入101例IBD患者，其中溃疡性结肠炎72例，克罗恩病29例。24周后，72例（71.3%）患者维持SC VDZ。在多变量分析中，在IBD整体队列（p=0.018）和UC患者（p=0.027）中，转换时使用皮质类固醇是24周SC VDZ失败的最强预测因子。Kaplan-Meier分析显示，UC患者IV给药间隔增加（p=0.021）、临床缓解失败（p=0.038）或在切换时同时使用皮质类固醇(p结论：切换时疾病活动性显著影响SC VDZ持续性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gut and Liver 医学-胃肠肝病学

CiteScore

7.50

自引率

8.80%

发文量

119

审稿时长

6-12 weeks

期刊介绍： Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut and Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. Gut and Liver is jointly owned and operated by 8 affiliated societies in the field of gastroenterology, namely: the Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, the Korean College of Helicobacter and Upper Gastrointestinal Research, the Korean Association for the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, the Korean Pancreatobiliary Association, and the Korean Society of Gastrointestinal Cancer.